Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

13 trials with published results (28%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.5%

3 terminated out of 46 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

22%

10 trials in Phase 3/4

Results Transparency

39%

13 of 33 completed with results

Key Signals

13 with results92% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (6)
Early P 1 (3)
P 1 (8)
P 2 (14)
P 3 (6)
P 4 (4)

Trial Status

Completed33
Unknown4
Recruiting3
Terminated3
Not Yet Recruiting2
Withdrawn1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 33 completed trials

Clinical Trials (46)

Showing 20 of 20 trials
NCT06923592Phase 3RecruitingPrimary

Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar

NCT05361486CompletedPrimary

Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

NCT07430592Phase 2Not Yet Recruiting

This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria

NCT05270265Early Phase 1TerminatedPrimary

Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine

NCT06575647Phase 4Completed

Vivax Elimination With Tafenoquine (VET) Study

NCT07172724Phase 1Not Yet RecruitingPrimary

Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."

NCT06666491Phase 3RecruitingPrimary

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

NCT05540470Not ApplicableCompletedPrimary

Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield

NCT05788094Phase 4Recruiting

ACT vs CQ With Tafenoquine for P. Vivax Mono-infection

NCT03797989Early Phase 1CompletedPrimary

VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection

NCT05044637Phase 2CompletedPrimary

Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children

NCT04201431Phase 1CompletedPrimary

Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1

NCT04411836Phase 3Completed

Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

NCT04079621Phase 4Completed

Short Course Radical Cure of P. Vivax Malaria in Nepal

NCT04009096Phase 2CompletedPrimary

VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines

NCT04709692Phase 2Completed

Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

NCT05753150CompletedPrimary

Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand

NCT06036030Phase 2Completed

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

NCT03377296Not ApplicableCompletedPrimary

Study of Controlled Human Plasmodium Vivax Infection

NCT05096702UnknownPrimary

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Scroll to load more

Research Network

Activity Timeline